Baicalein and IR780 Coloaded Liposomes for Antifungal and Anticancer Therapy

Triple-negative breast cancer (TNBC) is known for its aggressive nature, typically presenting as high-grade tumors that grow and spread quickly in all breast cancer types. Several studies have reported a strong correlation between cancer and microbial infections due to a compromised immune system. The most frequent infection associated with surface malignancies, including breast cancer, is Candidiasis, which is majorly caused by Candida albicans. This study reports the development and characterization of the drug Baicalein (B) and NIR dye IR780 (IR) coloaded liposomes (BIRLs) as a multifunctional nanoplatform for treating fungal infections and TNBC. BIRLs were prepared by using hydrogenated soybean phosphatidylcholine as the lipid matrix, enhancing both the drug and dye solubility and therapeutic efficacy. The synthesized BIRLs-mediated photothermal therapy (PTT) exhibited significant synergistic antifungal efficacy when tested against C. albicans. The biocompatibility of BIRLs was studied in fibroblast cell lines and zebrafish embryos. BIRLs demonstrated promising photothermal and photodynamic effects, synergistically enhancing tumor ablation and reactive oxygen species (ROS) generation upon near-infrared (NIR) laser irradiation. In vitro studies revealed that BIRLs exhibit potent anticancer activity in two-dimensional (2D) cell cultures and three-dimensional (3D) tumor spheroids, significantly inhibiting cancer cell proliferation and migration. The dual therapeutic effect of BIRLs was additionally demonstrated by their ability to inhibit fungal growth, addressing common complications in cancer patients with compromised immune systems. Overall, the results highlighted the promising application of BIRLs as a versatile nanoplatform for synergistic cancer therapy and as an antifungal agent, with the potential to significantly improve outcomes for TNBC patients.